SFNEP oncology nutrition guidelines: Place of immunonutrition in oncology;Nutrition chez le patient adulte atteint de cancer: Place de la pharmaconutrition en cancérologie

Nutrition Clinique et Metabolisme

Volumn 26, Issue 4, 2012, Pages 247-268

  Hébuterne, Xavier ^a   Bensadoun, René Jean ^b  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NUTRITION; PRACTICE GUIDELINE;

EID: 84870740887     PISSN: 09850562     EISSN: 17683092     Source Type: Journal    
DOI: 10.1016/j.nupar.2012.10.009     Document Type: Article

References (141)

1. Heyland D., Dhaliwal R. Immunonutrition in the critically ill: from old approach to new paradigms. Intensive Care Med 2005, 31:501-503.
2. Laviano A., Meguid M.M., Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003, 4:686-694.
3. Antoun S., Merad M., Nitenberg G., Ruffié P., Raynard B. Acide gras n-3 et cancer déclaré: intérêt réel ou effet de mode ?. Nutr Clin Metab 2005, 19:160-165.
4. Fürst P., Kuhn K.S. Fish oil emulsions: what benefits can they bring?. Clin Nutr 2000, 19:7-14.
5. Wigmore S.J., Ross J.A., Falconer J.S., Plester C.E., Tisdale M.J., Carter D.C., et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996, 12:S27-S30.
6. Gogos C.A., Ginopoulos P., Salsa B., Apostolidou E., Zoumbos N.C., Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer 1998, 82:395-402.
7. Barber M.D., Ross J.A., Preston T., Shenkin A., Fearon K.C. Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. J Nutr 1999, 129:1120-1125.
8. Barber M.D., Ross J.A., Voss A.C., Tisdale M.J., Fearon K.C. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999, 81:80-86.
9. Burns C.P., Halabi S., Clamon G.H., Hars V., Wagner B.A., Hohl R.J., et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 1999, 5:3942-3947.
10. Barber M.D., McMillan D.C., Preston T., Ross J.A., Fearon K.C. Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement. Clin Sci 2000, 98:389-399.
11. Wigmore S.J., Barber M.D., Ross J.A., Tisdale M.J., Fearon K.C. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000, 36:177-184.
12. Barber M.D., Fearon K.C., Tisdale M.J., McMillan D.C., Ross J.A. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer 2001, 40:118-124.
13. Bruera E., Strasser F., Palmer J.L., Willey J., Calder K., Amyotte G., et al. Effect of a fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebocontrolled study. J Clin Oncol 2003, 21:129-134.
14. Fearon K.C.H., Von Meyenfeldt M.F., Moses A.G.W., Van Geenen R., Roy A., Gouma D.J., et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003, 52:1479-1486.
15. Burns C.P., Halabi S., Clamon G.H., Hars V., Wagner B.A., Hohl R.J., et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 1999, 5:3942-3947.
16. Jatoi A., Rowland K., Loprinzi C.L., Sloan J.A., Dakhil S.R., Mac Donald N., et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a north central cancer treatment group and national cancer institute of Canada collaborative effort. J Clin Oncol 2004, 22:2469-2476.
17. Moses A.W., Slater C., Preston T., Barber M.D., Fearon K.C. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004, 90:996-1002.
18. de Luis D.A., Izaola O., Aller R., Cuellar L., Terroba M.C. A randomized clinical trial with oral Immunonutrition (omega3-enhanced formula vs. arginine-enhanced formula) in ambulatory head and neck cancer patients. Ann Nutr Metab 2005, 49:95-99.
19. Fearon K.C., Barber M.D., Moses A.G., Ahmedzai S.H., Taylor G.S., Tisdale M.J., et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006, 24:3401-3407.
20. Read J.A., Beale J.P., Volker D.H., Smith N., Childs A., Clarke S.J. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer 2007, 15:301-307.
21. Bayram I., Erbey F., Celik N., Nelson J.L., Tanyeli A. The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children. Pediatr Blood Cancer 2009, 52:571-574.
22. Murphy R.A., Mourtzakis M., Chu Q.S.C., Baracos V.E., Reiman T., Mazurak V.C. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 2011, 117(8):1775-1782.
23. May P.E., Barber A., D'Olimpio J.T., Hourihane A., Abumrad N.N. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg 2002, 183:471-479.
24. Berk L., James J., Schwartz A., Hug E., Mahadevan A., Samuels M., et al. RTOG. A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer 2008, 16:1179-1188.
25. Marik P.E., Zaloga G.P. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 2008, 34:1980-1990.
26. McCowen K.C., Bistrian B.R., Immunonutrition: problematic or problem solving. Am J Clin Nutr 2003, 77:764-770.
27. Daly J.M., Lieberman M.D., Goldfine J., Shou J., Weinstraub F., Rosato E.F., et al. Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic and clinical outcome. Surgery 1992, 112:56-67.
28. Daly J.M., Weintraub F.N., Shou J., Rosato E.F., Lucia M. Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann Surg 1995, 221:327-338.
29. Kenler A.S., Swails W.S., Driscoll D.F., DeMichele S.J., Daley B., Babineau T.J., et al. Early enteral feedung in postsurgical cancer patients. Fish oil structured lipid-based polymeric formula versus a standard polymeric formula. Ann Surg 1996, 223:316-333.
30. Gianotti L., Braga M., Vignali A., Balzano G., Zerbi A., Bisagni P., et al. Effect of route of delivery and formulation of postoperative nutritional support in patients undergoing major operations for malignant neoplasms. Arch Surg 1997, 132:1222-1229.
31. Senkal M., Mumme A., Eickhoff U., Geier B., Späth G., Wulfert D., et al. Early postoperative enteral immunonutrition: clinical outcome and cost-comparison analysis in surgical patients. Crit Care Med 1997, 25:1486-1489.
32. Braga M., Gianotti L., Vignali A., Cestari A., Bisagni P., Di Carlo V. Artificial nutrition after major abdominal surgery: impact of route of administration and composition of the diet. Crit Care Med 1998, 26:24-30.
33. Senkal M., Zumtobel V., Bauer K.H., Marpe B., Wolfram G., Frei A., et al. Outcome and cost-effectiveness of perioperative enteral immunonutrition in patients undergoing elective upper gastrointestinal tract surgery. Arch Surg 1999, 134:1309-1316.
34. Gianotti L., Braga M., Frei A., Greiner R., Di Carlo V. Health care resources consumed to treat postoperative infections: cost saving by perioperative immunonutrition. Shock 2000, 14:325-330.
35. Gianotti L., Braga M., Gentilini O., Balzano G., Zerbi A., Di Carlo V. Artificial nutrition after pancreaticoduodenectomy. Pancreas 2000, 21:344-351.
36. Riso S., Aluffi P., Brugnani M., Farinetti F., Pia F., D'Abdrea F. Postoperative enteral immunonutrition in head and neck cancer patients. Clin Nutr 2000, 19:407-412.
37. Braga M., Gianotti L., Nespoli L., Radaelli G., Di Carlo V. Nutritional approach in malnourished surgical patients. A prospective randomized study. Arch Surg 2002, 137:174-180.
38. Braga M., Gianotti L., Vignali A., Di Carlo V. Preoperative oral arginin e and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer. Surgery 2002, 132:805-814.
39. Gianotti L., Braga M., Nespoli L., Radaelli G., Beneduce A., Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology 2002, 122:1763-1770.
40. Farreras N., Artigas V., Cardona D., Rius X., Trias M., Gonzalez J.A. Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. Clin Nutr 2005, 24:55-65.
41. Horie H., Okada M., Kojima M., Nagai H. Favorable effects of preoperative enteral immunonutrition on a surgical site infection in patients with colorectal cancer without malnutrition. Surg Today 2006, 36:1063-1068.
42. Jo S., Choi S., Heo J., Kim E., Min M., Choi D., et al. Missing effect of glutamine supplementation on the surgical outcome after pancreaticoduodenectomy for periampullary tumors: a prospective, randomized, double-blind, controlled clinical trial. World J Surg 2006, 30:1974-1982.
43. Xu J., Zhong Y., Jing D., Wu Z. Properative enteral immunonutrition improves post-operative outcome in patients with gastrointestinal cancer. World J Surg 2006, 30:1284-1289.
44. Giger U., Bûchler M., Farhadi J., Berger D., Hüsler J., et al. Properative immunonutrition suppresses perioperative inflammatory response in patients with major abdominal surgery- A randomized controlled pilot study. Ann Surg Oncol 2007, 14:2798-2806.
45. Oguz M., Kerem M., Bedirli A., Mentes B., Sakrak O., Salman B., et al. L-Alanin-L-Glutamine supplementation improves the outcome after colorectal surgery for cancer. Colorectal Dis 2007, 9:515-520.
46. Takeuchi H., Ikeuchi S., Kawaguchi Y., Kitagawa Y., Isobe Y., Kubochi K., et al. Clinical significance of perioperative immunonutrition for patients with esophageal cancer. World J Surg 2007, 31:2160-2167.
47. Wichmann M.W., Thul P., Czarnetzki H.D., et al. Evaluation of a fish oil containing lipid emulsion (Lipoplus MLF541): data from a prospective, randomized, multicenter trial. Crit Care Med 2007, 35:700-706.
48. Klek S., Kulig J., Sierzega M., Szybinski P., Szczepanek K., Kubisz A., et al. The impact of immunostimulating nutrition on infectious complications after upper gastrointestinal surgery: a prospective, randomized, clinical trial. Ann Surg 2008, 248:212-220.
49. Klek S., Kulig J., Sierzega M., Szczepanek K., Szybiński P., Scislo L., et al. Standard and immunomodulating enteral nutrition in patients after extended gastrointestinal surgery--a prospective, randomized, controlled clinical trial. Clin Nutr 2008, 27:504-512.
50. Liang B., Wang S., Ye Y.J., Yang X.D., Wang Y.L., Qu J., et al. Impact of postoperative omega-3 fatty acid-supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients. World J Gastroenterol 2008 21, 14:2434-2439.
51. De Luis D.A., Izaola O., Cuellar L., Terroba M.C., Martin T., Aller R. High dose of arginine enhanced enteral nutrition in postsurgical head and neck cancer patients. A randomized clinical trial. Eur Rev Med Pharmacol Sci 2009, 13:279-283.
52. Gianotti L., Braga M., Biffi R., Bozzetti F., Mariani L. Perioperative intravenous glutamine supplementation in major abdominal surgery for cancer. Ann Surg 2009, 250(5):684-690.
53. Gunerhan Y., Koksal N., Sahin U., Uzun M., Eksioglu-Demiralp E. Effect of preoperative immunonutrition and other nutrition models on cellular immune parameters. World J Gastroenterol 2009, 15:467-472.
54. Ryan A.M., Reynolds J.V., Healy L., Byrne M., Moore J., Branelly N., et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg Oncol 2009, 249:355-363.
55. Sorensen D., McCarthy M., Baumgartner B., Demars S. Perioperative immunonutrition in head and neck cancer. Laryngoscope 2009, 119:1358-1364.
56. Buijs N., van Bokhorst-de van der Schueren M.A., Langius J.A., Leemans C.R., Kuik D.J., Vermeulen M.A., et al. Perioperative arginine-supplemented nutrition in malnourished patients with head and neck cancer improves long-term survival. Am J Clin Nutr 2010, 92:1151-1156.
57. Felekis D., Eleftheriadou A., Papadakos G., Bosinakou I., Ferekidou E., Kandiloros D., et al. Effect of perioperative immuno-enhanced enteral nutrition on inflammatory response, nutritional status, and outcomes in head and neck cancer patients undergoing major surgery. Nutr Cancer 2010, 62:1105-1112.
58. Jiang Z.M., Wilmore D.W., Wang X.R., Wei J.M., Zhang Z.T., Gu Z.Y., et al. Randomized clinical trial of intravenous soybean oil alone versus soybean oil plus fish oil emulsion after gastrointestinal cancer surgery. Br J Surg 2010, 97(6):804-809.
59. Klek S., Sierzega M., Szybinski P., Szczepanek K., Scislo L., Walewska E., et al. The immunomodulating enteral nutrition in malnourished surgical patients - A prospective, randomized, double-blind clinical trial. Clin Nutr 2010.
60. Sodergren M.H., Jethwa P., Kumar S., Duncan H.D., Johns T., Pearce C.B. Immunonutrition in patients undergoing major upper gastrointestinal surgery: a prospective double-blind randomised controlled study. Scand J Surg. 2010, 99:153-161.
61. Braga M., Gianotti L., Radaelli G., Vignali A., Mari G., Gentilini O., et al. Perioperative immunonutrition in patients undergoing cancer surgery. Results of a randomized double-blind phase 3 trial. Arch Surg 1999, 134:428-433.
62. Braga M., Gianotti L., Vignali A., Schmid A., Nespoli L., Di Carlo V. Hospital resources consumed for surgical morbidity: effects of preoperative arginine and omega-3 fatty acid supplementation on costs. Nutrition 2005, 21:1078-1086.
63. Helminen H., Raitanen M., Kellosalo J. Immunonutrition in elective gastrointestinal surgery patients. Scand J Surg 2007, 46:46-50.
64. Stableforth W.D., Thomas S., Lewis S.J. A systematic review of the role of immunonutrition in patients undergoing surgery for head and neck cancer. Int J Oral Maxillofac Surg 2009, 38:110-130.
65. Heys S.D., Walker L.G., Smith I., Eremin O. Enteral nutrition supplementation with key nutrients in patients with critical illness and cancer. A meta-analysis of randomized controlled clinical trial. Ann Surg 1999, 229:467-477.
66. Beale R.J., Bryg D.J., Bihari D.J. Immunonutrition in the critically ill: a systematic review on clinical outcome. Crit Care Med 1999, 27:2799-2805.
67. Heyland D.K., Novak F., Drover J.W., Jain M., Su X., Suchner U. Should immunonutrition become routine in critically ill patients? A systemic review of the evidence. JAMA 2001, 286:944-953.
68. Montejo J.C., Zarazaga A., Lopez-Martinez J., Urrutia G., Roque M., Blesa A.L., et al. Immunonutrition in the intensive care unit. A systematic review and consensus statement. Clin Nutr 2003, 22:221-233.
69. Waitzberg D.L., Daito H., Plank L., Jamieson G., Jagannath P., Hwang T., et al. Postsurgical infections are reduced with specialized nutriton support. World J Surg 2006, 30:1592-1604.
70. Marik P.E., Zaloga G.P. Immunonutrition in high-risk surgical patients: A systematic review and analysis of the literature. JPEN 2010, 34:378-386.
71. Fish J., Sporay G., Beyer K., Jones J., Kihara T., Kennedy A., et al. A prospective randomized study of glutamine-enriched parenteral compared with enteral feeding in postoperative patients. Am J Clin Nutr 1997, 65:977-983.
72. Morlion B.J., Stehle P., Wachtler P., Siedhoff H.P., Köller M., König W., et al. Total parenteral nutrition with glutamine dipeptide after major abdominal surgery: a randomized, double-blind, controlled study. Ann Surg 1998, 227:302-308.
73. Novak F., Heyland D.K., Avenell A., Drover J.W., X S. Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med 2002, 30:2022-2029.
74. Wischmeyer P. Glutamine: role in critical illness and ongoing clinical trial. Curr Opin Gastroenterol 2008, 24:190-197.
75. Goeters C., Wenn A., Mertes N., Wempe C., Van Aken H., Stehle P., et al. Parenteral L-alanyl-L-glutamine improves 6-month outcome in critically ill patients. Crit Care Med 2002, 30:2032-2037.
76. Déchelotte P., Hasselmann M., Cynober L., Allaouchiche B., Coëffier M., Hecketsweiler B., et al. L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: The French controlled, randomized, double-blind, multicenter study. Crit Care Med 2006, 34(3):598-604.
77. Yeh C.N., Lee H.L., Liu Y.Y., Chiang K.C., Hwang T.L., Jan Y.Y., et al. The role of parenteral glutamine supplement for surgical patient perioperatively: result of a single center, prospective and controlled study. Langenbecks Arch Surg 2008, 393:849-855.
78. Heller A.R., Fischer S., Rossel T., et al. Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery. Br J Nutr 2002, 87(Suppl. 1):S595-S601.
79. Tsekos E., Reuter C., Stehle P., Boeden G. Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery. Clin Nutr 2004, 23:325-330.
80. Senkal M., Geier B., Hannemann M., et al. Supplementation with omega-3 fatty acids in parenteral nutrition beneficially alters phospholipid fatty acid pattern. J Parenter Enteral Nutr 2007, 31:12-17.
81. Heller A.R., Rossel T., Gottlschiljch B., et al. Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. Br J Cancer 2004, 111:611-616.
82. Takagi K., Yamamori H., Furukawa K., et al. Perioperative supplementation of EPA reduces immunosuppression induced by postoperative chemoradiation therapy in patients with esophageal cancer. Nutrition 2001, 17:478-479.
83. Ziegler T.R., Young L.S., Benfell K., Scheltinga M., Hortos K., Bye R., et al. Clinical and metabolic efficacy of glutamine supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 1992, 116:821-828.
84. Schloerb P.R., Amare M. Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double-blind study). JPEN J Parenter Enteral Nutr 1993, 17:407-413.
85. Jebb S.A., Marcus R., Elia M. A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants. Clin Nutr 1995, 14:162-165.
86. Anderson P.M., Ramsay N.K., Shu X.O., Rydholm N., Rogosheske J., Nicklow R., et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 1998, 22:339-344.
87. Brown S.A., Goringe A., Fegan C., Davies S.V., Giddings J., Whittaker J.A., et al. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 1998, 22:281-284.
88. Schloerb P.R., Skikne B.S. Oral and parenteral glutamine in bone marrow transplantation: a randomized, doubleblind study. JPEN J Parenter Enteral Nutr 1999, 23:117-122.
89. Canovas G., Leon-Sanz M., Gomez P., Valero M.A., Gomis P., La Huerta J.J. Oral glutamine supplements in autologous hematopoietic transplant: impact on gastrointestinal toxicity and plasma protein levels. Haematologica 2000, 85:1229-1230.
90. Cockerham M.B., Weinberger B.B., Lerchie S.B. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother 2000, 34:300-303.
91. Coghlin Dickson T.M., Wong R.M., Offrin R.S., Shizuru J.A., Johnston L.J., Hu W.W., et al. Effect of oral glutamine supplementation during bone marrow transplantation. JPEN J Parenter Enteral Nutr 2000, 24:61-66.
92. Pytlik R., Benes P., Patorkova M., Chocenska E., Gregora E., Prochazka B., et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplant 2002, 30:953-961.
93. Piccirillo N., De Matteis S., Laurenti L., Chiusolo P., Sora F., Pittiruti M., et al. Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 2003, 88:192-200.
94. Aquino V.M., Harvey A.R., Garvin J.H., Godder K.T., Nieder M.L., Adams R.H., et al. A double-blind randomized placebocontrolled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 2005, 36:611-616.
95. Blijlevens N.M., Donnelly J.P., Naber A.H., Schattenberg A.V., DePauw B.E. A randomised, double-blinded, placebocontrolled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. Support Care Cancer 2005, 13:790-796.
96. Sykorova A., Horacek J., Zak P., Kmonicek M., Bukac J., Maly J. A randomized, double blind comparative study of prophylactic parenteral nutritional support with or without glutamine in autologous stem cell transplantation for hematological malignancies-three years' follow-up. Neoplasma 2005, 52:476-482.
97. da Gama Torres H.O., Vilela E.G., da Cunha A.S., Goulart E.M., Souza M.H., Aguirre A.C., et al. Efficacy of glutaminesupplemented parenteral nutrition on short-term survival following Allo-SCT: a randomized study. Bone Marrow Transplant 2008, 41:1021-1027.
98. Kuskonmaz B., Yalcin S., Kucukbayrak O., Cetin N., Cetin M., Tezcan I., et al. The effect of glutamine supplementation on hematopoietic stem cell transplant outcome in children: A case-control study. Pediatr Transplantation 2008, 12:47-51.
99. Pérez A.L., Fernández Vázquez A., Valero Zanuy M.A., Gomis Muñoz P., León Sanz M., Herreros de Tejada A. Parenteral nutrition supplemented with glutamine in patients undergoing bone marrow transplantation. Nutr Hosp 2010, 25:49-52.
100. Murray S.M., Pindoria S. Nutrition support for bone marrow transplant patients. Cochrane Database Syst Rev 2009, 1:CD002920.
101. Crowther M., Avenell A., Culligan D.J. Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. Bone Marrow Transplantation 2009, 44:413-425.
102. Bozzetti F., Bozzetti F., Arends J., Lundholm K., Micklewright A., Zurcher G., et al. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr 2009, 28:445-454.
103. Jebb S.A., Osborne R.J., Maughan T.S., Mohideen N., Mack P., Mort D., et al. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 1994, 70:732-735.
104. Skubitz K.M., Anderson P.M. Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J Lab Clin Med 1996, 127:223-228.
105. Bozzetti F., Biganzoli L., Gavazzi C., Cappuzzo F., Carnaghi C., Buzzoni R., et al. Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. Nutrition 1997, 13:748-751.
106. Anderson P.M., Schroeder G., Skubitz K.M. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 1998, 83:1433-1439.
107. Daniele B., Perrone F., Gallo C., Pignata S., De Martino S., De Vivo R., et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut. 2001, 48:28-33.
108. Jacobson S.D., Loprinzi C.L., Sloan J.A., Wilke J.L., Novotny P.J., Okuno S.H., et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 2003, 1:274-278.
109. Stubblefield M.D., Vahdat L.T., Balmaceda C.M., Troxel A.B., Hesdorffer C.S., Gooch C.L. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 2005, 17:271-276.
110. Pan C.X., Loehrer P., Seitz D., Helft P., Juliar B., Ansari R., et al. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology 2005, 69:63-70.
111. Li Y., Yu Z., Liu F., Tan L., Wu B., Li J. Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial. Tumori 2006, 92:396-401.
112. Okur A., Ezgü F.S., Tümer L., Cinasal G., Oguz A., Hasanoglu A., et al. Effects of oral glutamine supplementation on children with solid tumors receiving chemotherapy. Pediatr Hematol Oncol 2006, 23:277-285.
113. Choi K., Lee S.S., Oh S.J., Lim S.Y., Lim S.Y., Jeon W.K., et al. The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr 2007, 26:57-62.
114. Wang W.S., Lin J.K., Lin T.C., Chen W.S., Jiang J.K., Wang H.S., et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007, 12:312-319.
115. Strasser F., Demmer R., Böhme C., Schmitz S.F., Thuerlimann B., Cerny T., et al. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. Oncologist 2008, 13:337-346.
116. Loven D., Levavi H., Sabach G., Zart R., Andras M., Fishman A., et al. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care 2009, 18:78-83.
117. Ward E., Smith M., Henderson M., Reid U., Lewis I., Kinsey S., et al. The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. Eur J Clin Nutr 2009, 63:134-140.
118. Stokman M.A., Spijkervet F.K., Boezen H.M., Schouten J.P., Roodenburg J.L., de Vries E.G. Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res 2006, 85:690-700.
119. Worthington H.V., Clarkson J.E., Eden O.B. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2007, 17:CD000978.
120. van Zaanen H.C., van der Lelie H., Timmer J.G., Fürst P., Sauerwein H.P. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994, 74:2879-2884.
121. Decker-Baumann C., Buhl K., Frohmüller S., von Herbay A., Dueck M., Schlag P.M. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer 1999, 35:202-207.
122. Scheid C., Hermann K., Kremer G., Holsing A., Heck G., Fuchs M., et al. Randomized, double-blind, controlled study of glycyl-glutamine-dipeptide in the parenteral nutrition of patients with acute leukemia undergoing intensive chemotherapy. Nutrition 2004, 20:249-254.
123. Sornsuvit C., Komindr S., Chuncharunee S., Wanikiat P., Archararit N., Santanirand P., et al. effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. J Int Med Res 2008, 36:1383-1391.
124. Li Y., Ping X., Yu B., Liu F., Ni X., Li J. Clinical trial: prophylactic intravenous alanyl-glutamine reduces the severity of gastrointestinal toxicity induced by chemotherapy: a randomized crossover study. Aliment Pharmacol Ther 2009, 30:452-458.
125. Trotti A., Bellm L.A., Epstein J.B., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003, 66:253-262.
126. Isenring E.A., Capra S., Bauer J.D. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer 2004, 91:447-452.
127. Ravasco P., Monteiro-Grillo I., Marques V.P., Camilo M.E. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 2005, 27:659-668.
128. Ravasco P., Monteiro-Grillo I., Vidal P.M., Camilo M.E. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005, 23:1431-1438.
129. Yoshida S., Matsui M., Shirouzu Y., Fujita H., Yamana H., Shirouzu K. Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer. Ann Surg 1998, 227:485-491.
130. Huang E.Y., Leung S.W., Wang C.J., Chen H.C., Sun L.M., Fang F.M., et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 2000, 46:535-539.
131. Kozelsky T.F., Meyers G.E., Sloan J.A., Shanahan T.G., Dick S.J., Moore R.L., et al. double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol 2003, 21:1669-1674.
132. Cerchietti L.C., Navigante A.H., Lutteral M.A., Castro M.A., Kirchuk R., Bonomi M., et al. Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006, 65:1330-1337.
133. Algara M., Rodríguez N., Viñals P., Lacruz M., Foro P., Reig A., et al. Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. Int J Radiat Oncol Biol Phys 2007, 69:342-349.
134. Jazieh A.R., Younas A., Safa M., Redmond K., Buncher R., Howington J., et al. clinical trial of concurrent paclitaxel, carboplatin, and external beam chest irradiation with glutamine in patients with locally advanced non-small cell lung cancer. Cancer Invest 2007, 25:294-298.
135. Topkan E., Yavuz M.N., Onal C., Yavuz A.A. Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters. Lung Cancer 2009, 63:393-399.
136. Assenat E., Latournerie M., Thézenas S., Gaillet S., Janiszewski C., Flori N., et al. A prospective phase II study evaluating the efficacy of oral immune modulating formulae on acute oral mucositis during radiochemotherapy in head and neck neoplasms. Clin Nutr 2011, 6:e171-e177.
137. Turowski G.A., Rashid Z., Hong F., Madri J.A., Basson M.D. Glutamine modulates phenotype and stimulates proliferation in human colon cancer cell lines. Cancer Res 1994, 54:5974-5980.
138. Dupertuis Y.M., Benais-Pont G., Buchegger F., Pichard C. Effect of an immunonutrient mix on human colorectal adenocarcinoma cell growth and viability. Nutrition 2007, 23:672-680.
139. Bougnoux P., Hajjaji N., Ferrasson M.N., Giraudeau B., Couet C., Le Floch O. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 2009, 101:1978-1985.
140. West N.J., Clark S.K., Phillips R.K., Hutchinson J.M., Leicester R.J., Belluzzi A., et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 2010, 59:918-925.
141. Murphy R.A., Mourtzakis M., Chu Q.S.C., Baracos V.E., Reiman T., Mazurak V.C. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced non small cell lung cancer. Cancer 2011, 15:3774-3780.